With Sandoz delivering first-quarter growth thanks to its booming biosimilars business – and despite flat sales of small-molecule generics that suffered from a downturn in North America – the company is “well on track to surf the biosimilars wave,” according to one analyst. However, Sandoz did report a delay to progress with its natalizumab biosimilar in the US that will push back launch.

Lupin has pushed into the Canadian biosimilars market with the launch of its Rymti rival to Amgen’s Enbrel. The launch is taking place via Lupin’s local partner Sandoz.

Sandoz has secured a launch date for its newly-approved US denosumab biosimilars, settling patent litigation with Prolia/Xgeva originator Amgen.

With Teva and Viatris recently under new management and Sandoz having last year split from former parent company Novartis, the three off-patent industry leaders are adopting different strategies for how they balance their generics and biosimilars interests with more innovative ventures. Generics Bulletin takes a look at the bigger picture.